Bioplus Co.
BioPlus Co., Ltd. is a South Korean KOSDAQ-listed biomedical company that develops hyaluronic acid fillers, medical devices, and cosmeceuticals using proprietary MDM® technology and DVS crosslinking. It serves aesthetic clinics and hospitals globally and is expanding into biopharmaceuticals via strategic biotech investments.
- Company typePublic
- Founded2003
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bioplus Co. does
BioPlus Co., Ltd. is a South Korea-based biomedical device and biopharmaceutical company founded in 2003 and listed on KOSDAQ (ticker 099430) since September 2021. The company specializes in hyaluronic acid (HA)-based products built on its proprietary MDM® Technology platform, which combines Micro Bead Monophasic Technology (MBMT), Divinyl sulfone Multi-Crosslink Technology (DMCT), and Multiple Degree Amphiphilic Purification (MDAP). BioPlus is the only company globally using DVS rather than BDDE as the cross-linking agent for HA dermal fillers, supporting a premium positioning with products priced approximately 5x above competitors and generating a 48.7% operating margin in 2021.
The company's product portfolio spans three categories: (1) MDM® Filler products including SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, and IPCHE for aesthetic applications; (2) Medical devices including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), and Blad-Care (cystitis treatment); and (3) Cosmeceutical/mesotherapy products under the Kiara and Labella brands. BioPlus derives approximately 85% of revenue from HA fillers and serves medical aesthetic clinics, hospitals, and orthopedic/surgical providers across Korea, China, the U.S., Europe, the Middle East, South Asia, Latin America, and Southeast Asia.
BioPlus operates a sales-led go-to-market with premium pricing, combining direct sales to medical institutions, franchise hospital operations in China's Hainan medical tourism zone, and exclusive distribution partnerships — most notably the BioPlus-Chimin (Haenam) joint venture for all-China distribution. Revenue scaled from 17B KRW in 2019 to 37.4B KRW in 2021 (~$28M USD), and the company has aggressively expanded into biopharmaceuticals through controlling and minority equity stakes in UbiProtein (52.96%, botulinum toxin and GLP-1), Novelgen (5.53%, virus treatments), ProCell Therapeutics (7.3%, next-gen botulinum toxin), and Ora Bio (43.4%, botulinum toxin strain), with a committed 200 billion KRW Seongbon Industrial Complex facility to scale production roughly 10x.
Bioplus Co. firmographics
Firmographics- Name
- Bioplus Co.
- Legal name
- BioPlus Co., Ltd.
- Website
- https://ubioplus.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioPlus Co., Ltd. is a South Korean KOSDAQ-listed biomedical company that develops hyaluronic acid fillers, medical devices, and cosmeceuticals using proprietary MDM® technology and DVS crosslinking. It serves aesthetic clinics and hospitals globally and is expanding into biopharmaceuticals via strategic biotech investments.
- Ownership category
- akta.pro rank
Bioplus Co. industry classification
Industry- Product category
- Aesthetic Medical Devices & Dermal Fillers
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (33911), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industries
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where Bioplus Co. is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices5 records
Markets served
Bioplus Co. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Hyaluronic Acid Fillers: Sales of MDM HA dermal fillers including SkinPlus-Hyal, Bio+ Dew, HyalDew series, DeneB, IPCHE products. Premium DVS-based fillers priced 5x higher than competitors with 48.7% operating profit margin in 2021.
- Medical Devices: Medical device products including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), Blad-Care (cystitis treatment). Products approved by various regulatory bodies including UK MHRA.
- Cosmeceuticals/Mesotherapy: Cosmeceutical products including Kiara, KiaraReju, KiaraPlus Aura, SlimSlimmer, LumiDew, Labella series for skin rejuvenation, hydration, and aesthetic treatments.
- Technology Licensing: Technology transfer of anti-adhesion drugs and other biomaterials to global companies for overseas regions. Joint development agreements with technology partnerships.
- Franchise Hospital Operations: Direct beauty and plastic surgery franchise hospital operations in China through Hainan subsidiary, targeting breast and vaginal plastic surgery markets not allowed in mainland China.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Premium DVS-based HA fillers priced significantly higher than competitors |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Bioplus Co. product offering
Product offeringCore offering
BioPlus manufactures and sells hyaluronic acid-based biomedical products across three categories: (1) MDM® dermal fillers (SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, IPCHE) for aesthetic procedures; (2) medical devices including InterBlock anti-adhesion barrier, HyalSyno synovial fluid replacement, and Blad-Care cystitis treatment; and (3) cosmeceutical/mesotherapy products (Kiara, Labella, Juvenihill). Products are sold to medical professionals and clinics domestically and exported internationally, leveraging proprietary MDM® Technology platform with DVS-based crosslinking.
Product overview
BioPlus Co., Ltd. is a biomedical device and pharmaceutical company specializing in hyaluronic acid-based products developed through its proprietary MDM® Technology platform. The company operates across three main product categories: (1) MDM Fillers including SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, and IPCHE products for aesthetic applications; (2) Medical devices including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), and Blad-Care (cystitis treatment); and (3) Cosmeceutical mesotherapy products under the Kiara and Labella brands. The MDM Technology platform combines MBMT (Micro Bead Monophasic Technology), DMCT (Divinyl sulfone Multi-Crosslink Technology), and MDAP (Multiple Degree Amphiphilic Purification) to create differentiated hyaluronic acid-based biomaterials with enhanced safety and efficacy.
Differentiator
Problem solved
Functional benefit
Products and services
- SkinPlus-Hyal (MDM Filler) Hyaluronic acid dermal filler utilizing proprietary MDM technology for wrinkle treatment and facial augmentation.
- Bio+ Dew
Quantifiable outcome
- Operating profit margin of 48.7% in 2021, significantly exceeding competitors in 10-30% range
- +2 more outcomes
Companies that use Bioplus Co.
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Bioplus Co. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Bioplus Co. partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- PHI BIOMEDcoreCo-development agreement for biocompatible polymer-based drug delivery system to improve stability and sustainability of biopharmaceuticals. Goal is to develop smart nano-medicine combining BioPlus biopharmaceuticals with PHI Biomed's polymer formulation technology. Collaboration in distribution, sale, and commercialization of existing and newly developed products.
- UbiProteincoreBioPlus acquired 52.96% stake for 2.625 billion KRW to secure management rights. UbiProtein is a platform company with 22 types of biobetter protein drug patents including AUT (Anti-Ubiquitization Technology) for protein half-life enhancement. Enables development of improved botulinum toxin, GLP-1 obesity/diabetes treatments.
- Chimin Health ManagementcoreBusiness cooperation contract for medical device business in China including hyaluronic acid fillers and agents. Joint venture Bioplus-Chimin (Haenam) Co., Ltd. established for import license and exclusive distribution rights across all China regions. Products include HyalDew filler, InterBlock anti-adhesion, HyalSyno articular lubricant, Blad-Care cystitis treatment.
- NoblegencoreJoint development agreement for virus treatments. Noblegen provides NVG308 mini-antibody pipeline effective against COVID-19 and influenza viruses. BioPlus handles substance production, clinical trials, licensing, and sales. Expansion from earlier BioPlus-Noblegen agreement to include nano-sized biopolymer technology.
- Gachon University (Prof. Kim Moon-il, Prof. Kim Il-tae)minorMOU for joint development of virus treatments incorporating nano-sized biopolymer technology from Gachon University as original technology. Development of treatments for COVID-19, AIDS, hepatitis using stabilized antiviral antibodies.
- UROALL (Prof. Park Myung-chan, Inje University)minorMOU for joint development of medical device combining BioPlus InterBlock anti-adhesion drug with UROALL's drug-releasing catheter for urethral stenosis prevention and treatment.
- Ora BiominorTechnology cooperation contract for ubi protein Co., Ltd. to establish foothold for biobetter business development.
Scale indicators12 records
Recent moves8 records
Expansion highlights6 records
Bioplus Co. competitors and assessment
Company assessmentBroad incumbents
- Galderma: World's largest pure-play dermatology company and maker of the Restylane HA filler franchise, competing head-to-head with BioPlus in aesthetic HA fillers. Comparable in HA filler technology focus and product positioning, but with established global distribution, broader aesthetics portfolio, and a multi-decade safety database that BioPlus lacks.
- Allergan Aesthetics (AbbVie): Global aesthetics market leader and maker of the Juvederm HA dermal filler franchise, plus Botox. Directly comparable to BioPlus in HA filler category but operates at vastly greater scale, with FDA-cleared products in the US and global commercial reach that BioPlus is still building.
- LG Chem (LG Life Sciences): Major Korean chemical and life sciences company producing Yvoire HA dermal fillers. Comparable to BioPlus in HA filler technology but embedded in a much larger diversified industrial conglomerate with global distribution and substantially greater R&D resources.
- Merz Aesthetics: Global aesthetics player selling Belotero HA dermal fillers, Radiesse biostimulator, and Ultherapy. Comparable to BioPlus in the HA filler category but serves a broader aesthetics portfolio and operates at significantly larger scale across all major geographies.
Direct peers
- Sinclair Pharma: European aesthetics company with HA fillers, biostimulators, and thread lifting products, recently acquired by Huadong Medicine. Comparable to BioPlus in premium aesthetics positioning and international expansion ambitions, with a similarly broad product portfolio spanning HA and adjacent aesthetics.
- Hugel: South Korean aesthetics company with Botulax (botulinum toxin) and dermal filler products, listed on KOSDAQ. Direct Korean peer to BioPlus in aesthetics, with similar premium positioning in Korea and overlapping international expansion strategies, but at materially larger scale and with established botulinum toxin leadership.
- Anika Therapeutics: US-based company specializing in HA-based products including joint health (viscosupplementation, comparable to HyalSyno) and regenerative aesthetics. Directly comparable to BioPlus's medical device business (InterBlock, HyalSyno) and provides a public-market comp for the HA platform value of BioPlus.
- Medytox: Korean aesthetic biopharmaceutical company developing Neuronox botulinum toxin and HA dermal fillers, KOSDAQ-listed. Most direct Korean comp to BioPlus in combining HA fillers with adjacent biopharma (botulinum toxin) and competing in similar export markets.
- Teoxane: Swiss premium HA dermal filler company (Teosyal range) competing in the same premium aesthetic segment as BioPlus. Both companies emphasize proprietary crosslinking technology and premium pricing, making Teoxane one of the closest direct comps to BioPlus's DVS-based positioning, though Teoxane uses traditional BDDE chemistry.
Regional players
- Daewoong Pharmaceutical: Korean pharmaceutical company selling Nabota botulinum toxin and aesthetic products, with a direct interest in the same anti-adhesion and biopharmaceutical adjacencies BioPlus is pursuing. Regional Korean comp with similar product portfolio expansion strategy but with established US FDA approval for Nabota that BioPlus lacks.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bioplus Co. social profiles
Digital presenceBioplus Co. compliance and trust
Trust signalCompliance5 records
Bioplus Co. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioplus Co. leadership team
Management profileNumber of profiles
Profiles1 record
Bioplus Co. subsidiaries and ownership
Company hierarchySubsidiaries3 records
Bioplus Co. funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioplus Co. M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioplus Co.
What does Bioplus Co. do?
BioPlus manufactures and sells hyaluronic acid-based biomedical products across three categories: (1) MDM® dermal fillers (SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, IPCHE) for aesthetic procedures; (2) medical devices including InterBlock anti-adhesion barrier, HyalSyno synovial fluid replacement, and Blad-Care cystitis treatment; and (3) cosmeceutical/mesotherapy products (Kiara, Labella, Juvenihill). Products are sold to medical professionals and clinics domestically and exported internationally, leveraging proprietary MDM® Technology platform with DVS-based crosslinking.
Is Bioplus Co. a public or private company?
Bioplus Co. is a public company. It is classified as public and is currently operating.
When was Bioplus Co. founded?
Bioplus Co. was founded in 2003. It employs 51 to 100 people.
Where is Bioplus Co. based?
Bioplus Co. is headquartered in Seongnam, South Korea, in the Asia region.
How does Bioplus Co. make money?
Five revenue lines are on record. Hyaluronic Acid Fillers are the primary driver. The others are medical Devices, cosmeceuticals/Mesotherapy, technology Licensing and franchise Hospital Operations.
Who are Bioplus Co.'s main competitors?
Broad incumbents on record are Galderma, Allergan Aesthetics (AbbVie), LG Chem (LG Life Sciences) and Merz Aesthetics. Direct peers are Sinclair Pharma, Hugel, Anika Therapeutics, Medytox and Teoxane. Daewoong Pharmaceutical is listed as a regional player.
Does Bioplus Co. have an API?
No public API is recorded for Bioplus Co..
What industry is Bioplus Co. in?
Bioplus Co.'s product category is Aesthetic Medical Devices & Dermal Fillers. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 3254 and its SIC code is 2844.